The U.S. Food and Drug Administration (FDA) announces the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations to  “provide product specific guidance on the design of BE studies to support abbreviated new drug  applications.” Comments may be submitted at any time, but FDA suggests submitting them by June 2,  2014, to ensure consideration before the agency begins work on the final version.